SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis
Metabolic reprogramming, such as alterations in glutamine metabolism or glycolysis, is the hallmark of hepatocellular carcinoma (HCC). However, the underlying mechanisms are still incompletely elucidated. Previous studies have identified that methyltransferase SET and MYND domain-containing protein...
Main Authors: | Kangdi Xu, Jun Ding, Lingfeng Zhou, Dazhi Li, Jia Luo, Wenchao Wang, Mingge Shang, Bingyi Lin, Lin Zhou, Shusen Zheng |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/12/1/25 |
Similar Items
-
Targeting Epigenetic Changes Mediated by Members of the SMYD Family of Lysine Methyltransferases
by: Alyssa Padilla, et al.
Published: (2023-02-01) -
Identifying novel SMYD3 interactors on the trail of cancer hallmarks
by: Candida Fasano, et al.
Published: (2022-01-01) -
The chromatin remodeling factors EP300 and TRRAP are novel SMYD3 interactors involved in the emerging ‘nonmutational epigenetic reprogramming’ cancer hallmark
by: Candida Fasano, et al.
Published: (2023-01-01) -
SMYD3 Modulates the HGF/MET Signaling Pathway in Gastric Cancer
by: Katia De Marco, et al.
Published: (2023-10-01) -
The Lysine Methylase SMYD3 Modulates Mesendodermal Commitment during Development
by: Raffaella Fittipaldi, et al.
Published: (2021-05-01)